PDUFA IV: You Can't Always Get What You Want
This article was originally published in RPM Report
Former Senate HELP Committee FDA counsel Steven Irizarry looks ahead at the reauthorization of PDUFA and what drug companies should expect in the latest round of negotiations.
You may also be interested in...
A government shutdown was averted but not until federal agency’s were forced to communicate their shutdown plans to employees and the public. Those plans may have a lingering impact—and not just because the threat of a shutdown is sure to arise again.
The debate over an abbreviated biologics pathway took a big step forward with the Food & Drug Administration's approval of Sandoz' recombinant human growth hormone Omnitrope. The approval itself is precedent setting, but the bigger ramifications are political: the action steps up the pressure on Congress to address the issue head-on.
The intensely negative advisory committee for Biogen’s proposed Alzheimer’s therapy was a shocker. Would it have happened if US FDA had been able to convene an in-person event instead of a ‘virtual’ one?